HK1141447A1 - Pharmaceutical composition for the treatment of proliferative diseases - Google Patents

Pharmaceutical composition for the treatment of proliferative diseases

Info

Publication number
HK1141447A1
HK1141447A1 HK10107872.6A HK10107872A HK1141447A1 HK 1141447 A1 HK1141447 A1 HK 1141447A1 HK 10107872 A HK10107872 A HK 10107872A HK 1141447 A1 HK1141447 A1 HK 1141447A1
Authority
HK
Hong Kong
Prior art keywords
treatment
pharmaceutical composition
proliferative diseases
proliferative
diseases
Prior art date
Application number
HK10107872.6A
Inventor
Kaihong Yuan
Piaoyang Sun
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of HK1141447A1 publication Critical patent/HK1141447A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/282Platinum compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
HK10107872.6A 2008-09-16 2010-08-18 Pharmaceutical composition for the treatment of proliferative diseases HK1141447A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2008101496507A CN101675930B (en) 2008-09-16 2008-09-16 Pharmaceutical composition for treating hyperplasia diseases

Publications (1)

Publication Number Publication Date
HK1141447A1 true HK1141447A1 (en) 2010-11-12

Family

ID=42028743

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107872.6A HK1141447A1 (en) 2008-09-16 2010-08-18 Pharmaceutical composition for the treatment of proliferative diseases

Country Status (3)

Country Link
CN (1) CN101675930B (en)
HK (1) HK1141447A1 (en)
WO (1) WO2010031265A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102271848B1 (en) * 2013-11-01 2021-07-01 피트니 파마슈티컬스 피티와이 리미티드 Pharmaceutical combinations for the treatment of cancer
CN104086484B (en) * 2014-07-08 2016-05-25 上海宣创生物科技有限公司 Mesylate solvate crystal of nicotinamide derivative and its preparation method and application
CN104072412A (en) * 2014-07-08 2014-10-01 上海宣创生物科技有限公司 Mesylate B crystal form of nicotinamide derivative, preparation method and application of mesylate B crystal form
CN105541708A (en) * 2014-10-28 2016-05-04 华东理工常熟研究院有限公司 New crystal form of apatinib sulfate
CN105622499A (en) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 New crystal of apatinib sulfate
CN105622498A (en) * 2014-10-28 2016-06-01 华东理工常熟研究院有限公司 New crystal of apatinib sulfate
CN106176757B (en) * 2015-05-25 2019-12-10 江苏恒瑞医药股份有限公司 application of combination of compound and tegafur in preparation of medicine for treating proliferative diseases
CN107669685A (en) * 2016-08-02 2018-02-09 江苏恒瑞医药股份有限公司 A Pa combines for preparing the purposes in the medicine for treating stomach cancer for Buddhist nun with Tegafur and Taxane family
TWI764943B (en) 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 Combination use of anti-pd-1 antibody and vegfr inhibitor in the preparation of a medicament for the treatment of cancer
JP2021508699A (en) 2017-12-29 2021-03-11 江蘇恒瑞医薬股▲ふん▼有限公司 Use of combined treatment with PD-1 antibody and apatinib to treat triple-negative breast cancer
CN108409647B (en) * 2018-03-14 2020-03-24 盐城师范学院 Preparation method of apatinib
CN108524938B (en) * 2018-06-15 2020-06-19 深圳大学 Application of CDK6 small-molecule inhibitor in reducing tolerance of liver cancer cells to antitumor drugs or radiotherapy
CN110841607B (en) * 2019-11-22 2020-07-24 中国科学院地质与地球物理研究所 Ultra-low-cost priming gold special-effect resin and preparation and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1281590C (en) * 2002-11-27 2006-10-25 南京凯衡科贸有限公司 Hexavalent amino amidate derivative with function of inhibiting blood vessel growth activity

Also Published As

Publication number Publication date
WO2010031265A1 (en) 2010-03-25
CN101675930A (en) 2010-03-24
CN101675930B (en) 2012-04-25

Similar Documents

Publication Publication Date Title
IL200862A0 (en) 3-imidazolyl-indoles for the treatment of proliferative diseases
HK1141447A1 (en) Pharmaceutical composition for the treatment of proliferative diseases
SI2001892T1 (en) Imidazolothiazole compounds for the treatment of proliferative diseases
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
HK1154575A1 (en) Unsymmetrical pyrrolobenzodiazepine-dimers for treatment of proliferative diseases
IL224544B (en) Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
LT2303330T (en) Pharmaceutical compositions for treatment of parkinson`s disease
EP2291157A4 (en) Compositions and methods for the transdermal delivery of pharmaceutical compounds
IL207546A0 (en) Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
PT2358373E (en) Injectable polydeoxyribonucleotide composition for the treatment of osteoarticular diseases
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2213303A4 (en) Pharmaceutical composition for treatment of cataract
ZA201009072B (en) Pharmaceutical composition for the treatment of premature ejaculation
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
HK1155659A1 (en) Pharmaceutical composition for treatment of fibromyalgia
PL2604264T3 (en) Pharmaceutical composition for treating viral diseases
EP2142566A4 (en) Methods and compositions for the treatment of proliferative diseases
PL385972A1 (en) Pharmaceutical composition for therapy of parodonthium deseases
IL200753A (en) Pharmaceutical composition comprising ib-meca for the treatment of psoriasis
ZA201204341B (en) Pharmaceutical composition for treating gutaneous burns
EP2402342A4 (en) Pharmaceutical composition for treatment of 2 type diabetes
PL2344166T3 (en) Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
EP2467492A4 (en) Methods and compositions for the treatment of proliferative and pathogenic diseases
EP2329824A4 (en) Novel pharmaceutical composition for treatment of nociceptive pain

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220911